Randomised phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
Year: 2009
Session type: Poster / e-Poster / Silent Theatre session
1University Hospital Ghent, Belgium, 2Queen Elizabeth Hospital, Woodville, Australia, 3Uzhgorod National University, Ukraine, 4Hospital Clinico Universitario, Valencia, Spain, 5Institut Gustave Roussy, Villejuif, France, 6Hpital Piti-Salptrire, Paris, France, 7Vanderbilt University Medical Center, Tennessee, USA, 8Nationales Centrum fr Tumourerkrankungen, Heidelberg, Germany, 9Amgen Inc, California, USA
Abstract
Background
Panitumumab (pmab) is a fully human anti‑epidermal growth factor receptor monoclonal antibody approved as monotherapy for pts with mCRC.
